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ABSTRACT
The main detectors used for clinical dosimetry are ionisation chambers and
semiconductors. Thermoluminescent (TL) dosimeters are also of interest because of
their following advantages: i) wide useful dose range, ii) small physical size, iii) no need
for high voltage or cables, i.e. stand alone character, and iv) tissue equivalence (LiF) for
most radiation types. TL detectors can particularly be used for the absorbed dose
measurements performed with the aim to investigate cases where dose prediction is
difficult and not as part of a routine verification procedure. In this thesis, the
applicability of TL detectors was studied in different clinical applications. Particularly,
the major phenomena (e.g. energy dependence, sensitivity to high LET radiation,
reproducibility) affecting on the precision and accuracy of TL detectors in the dose
estimations were considered in this work.
In organ dose determinations of diagnostic X-ray examinations, the TL detectors
were found to be accurate within 5% (1 S.D.). For in vivo studies using internal
irradiation source, i.e. for systemic radiation therapy, a method for determining the
absorbed doses to organs was introduced. The TL method developed was found to be
able to estimate the absorbed doses to those critical organs near the body surface within
50%. In the mixed neutron-gamma field of boron neutron capture therapy (BNCT), TL
detectors were used for gamma dose and neutron fluence measurements. They were
found able to measure the neutron dose component with the accuracy of 16%, and
therefore to be a useful addition to the activation foils in BNCT neutron dosimetry. The
absorbed gamma doses can be measured with TL detectors within 20% in the mixed
neutron-gamma field, which enables in vivo measurements at BNCT beams with
approximately the same accuracy.
In this study, the uncertainties of TL dosimeters were found to be high but not
essentially greater than those in other measurement techniques used for clinical
dosimetry. Therefore, it is concluded, that the TL dosimeters are capable of determining
the absorbed doses to tissue in different clinical exposure conditions.
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1 AIM OF THE PRESENT STUDY
TL dosimeters are widely used in clinical applications. The aim of this thesis is to
determine the abilities of TL dosimeters in terms of precision and accuracy in measuring
the absorbed doses in macroscopic level to patients, and to phantoms. For this work, the
dose estimations have been done in the cases of
1) diagnostic X-ray studies (paper I)
2) gamma ray irradiations (paper II)
3) mixed neutron-gamma field irradiations (paper III)
The special technology required by the mixed neutron-gamma field is concerned in
papers IV, V and VI.
2 INTRODUCTION
Absorbed dose is defined as an amount of energy absorbed per unit mass of an irradiated
material [1]. It is a quantity of fundamental interest, and may be specified in any
medium for any type of ionising radiation. Clinical dosimetry is performed in order to
determine absorbed doses to patients who are exposed to ionising radiation, either for
therapy or diagnosis.
In therapy, the absorbed dose distribution in a phantom must be known to ensure
that the prescribed absorbed dose is delivered to the target volume in the patient.
Furthermore, while the measurement of absorbed dose distribution in a phantom is
essential in treatment planning, the ultimate check on the absorbed dose delivered to the
patient can only be made by in vivo absorbed dose measurements. Therefore, the
applications of clinical dosimetry in radiation therapy may be divided into groups
according to the used method [2]: i) in vivo measurements in the region of interest or at
some convenient region of the body, ii) in vitro measurements, and iii) measurements in
anatomical phantoms. The most useful phantom for absorbed dose measurements both
in radiation therapy and diagnostic radiology is one which is designed, as far as it is
practicable, to simulate the structure of the human body.
Traditionally, dosimetry in diagnostic radiology [2] has been mainly restricted to
personnel dosimetry and local investigations, but also it has a broader application for
instance by checking the quality of the used irradiation beams. According to the national
and international guidelines, e.g. EU directives, the absorbed doses to the patients,
exposed to radiation from diagnostic radiology, have to be determined [3]. Therefore, in
vivo measurements on patients undergoing radiological examinations or nuclear
medicine studies are performed. Also, as in therapy, anatomical phantoms are useful for
absorbed dose measurements in diagnostics.
In clinical practice, the main detectors used for dosimetry are ionisation chambers
and semiconductors. Ionisation chambers are commonly used for phantom
measurements because of their accuracy and practicality [4,5], but for in vivo
measurements they are not frequently used because of the high voltage applied and the
cables attached to the chamber. Semiconductor diodes are routinely used for absorbed
dose measurements of clinical studies. These measurements make use of the advantages
of semiconductors, such as ease of handling and the dose determination in real time
[6,7,8,9]. Thermoluminescent (TL) dosimeters are widely used for radiation detection in
the fields of environmental, industrial and personnel applications, just to mention a few.
The theory of TL dosimetry, and the abilities of different TL materials for use in several
applications, have been summarised in a variety of books [10,11,12,13,14,15,16]. The
main advantages of TL dosimeters are [17]: i) wide useful dose range, ii) small physical
size, iii) reusability and therefore, iv) economy, v) no need for high voltage or cables,
i.e. stand alone character, and vi) tissue equivalence (LiF) for most radiation types.
These make TL detectors a useful tool for clinical dosimetry; since its first use for in
vivo dosimetry during radiotherapy [18], the use of TL detectors has become an
important technique for clinical dosimetry [12,13,14,19,20,21].
Two important characteristics of the detectors used for clinical dosimetry are
precision and accuracy, defined as follows [13]:
Precision is a term related to the random uncertainties associated with the
measurement, i.e. the uncertainties that have been derived by statistical
methods from a number of repeated readings. In order to define the
precision of a set of measurements, the standard deviation may be used.
Accuracy is a statement of the closeness with which a measurement is
expected to approach the true value. Accuracy includes the effect of both
systematic and random uncertainties. The value of a quantity is understood
to be considered as ”true” either by theoretical considerations or by
comparison with a fundamental measurement. The indicated value is the
value of a quantity as indicated by the relevant measuring device,
sometimes also called ”reading” or measured value.
The precision and accuracy of TL dosimeters in the dose estimations is composed of
several parameters [13,22]. The sources of errors that affect the precision and accuracy
in determining the absorbed dose have been studied and reviewed by Robertson [23],
and more recently in the field of clinical applications by Toivonen [24,25]. According to
Toivonen, the accuracy requirements [26,27] of the conventional radiotherapy,
performed with external radiotherapy beams with photons and electrons, can be
achieved using TL detectors.
TL detectors can be, and commonly are, used for the absorbed dose measurements
performed with the aim to investigate cases where dose prediction is difficult and not as
part of a routine verification procedure. Among these cases are, for example, new
radiotherapies which have been developed for patient treatment during the past decades.
Absorbed dose determination in these radiotherapies, e.g. radioimmunotherapy and
boron neutron capture therapy, is more complicated (see e.g. refs. [28,29,30,31])
compared with the external radiotherapy. High uncertainties may be present in the dose
determination due to patient anatomy, i.e. geometry, inaccurate irradiation source
definition or the radiation quality, among other things.
In this thesis, the abilities of TL dosimeters in terms of precision and accuracy are
studied in different clinical exposure conditions: i) phantom studies with external X-
rays, ii) phantom and in vivo patient studies using internal irradiation source emitting
gamma radiation, and iii) phantom studies with an external epithermal neutron beam
containing a gamma ray component.
3 ABSORBED DOSE MEASUREMENTS
3.1 Diagnostic X-rays
In X-ray diagnostics, TL dosimeters are commonly used for determining absorbed doses
to patients [32,33,34,35], as well as in phantom studies [36,37]. For this study (paper I),
TLD-100 (LiF:Mg,Ti) TL dosimeters from Harshaw1 were used to measure the absorbed
doses. The measurements were performed in a Alderson-Rando phantom [38], which is
a commercially available phantom2 with anatomical unhomogenities in respect to the
lungs and skeleton. Four different X-ray examinations were performed: abdomen AP,
chest PA, skull LAT and modified lumbar spine LAT (paper I). In the irradiations, the
TL dosimeters were fixed into the holes of the Alderson-Rando phantom (see Fig. 2a in
paper I) so that the flat surface of the detector always faced the beam. The absorbed
doses to various organs of the phantom were derived from the doses of the reference
points, i.e. those points measured directly with TL detectors or interpolated from them.
3.2 Internal gamma ray source
In systemic radiation therapy (SRT), e.g. in radioimmunotherapy (RIT) with tumour-
associated monoclonal antibodies [39], internally administered radionuclides are used
for the treatment of cancer. For therapy, it is essential to know the absorbed doses for
besides the tumour also for normal tissues, especially to those critical organs limiting
the treatment. The dose estimations for RIT are frequently performed using calculation
methods: MIRD formalism [40,41,42,43] or the point dose kernel technique [44,45].
However, there is also a need to measure the absorbed doses in SRT [46,47].
Dose estimation methods in RIT have recently been summarised by Fisher [28],
Buchsbaum and Wessels [48], and Strand et al. [29]. New methods to measure the
absorbed doses with implanted TL dosimeters have been developed. However, so far the
mini-TL dosimeters have been implanted only into animals and tumour model systems
receiving RIT [49,50,51,52,53]; no results with patients have been reported. There are
certain limitations in direct organ dose measurements with the implantation of
dosimeters in the tumour or in the critical organs. These are mainly the decay of detector
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sensitivity with time [46,47,54,55] and the requirement for surgical procedures.
Therefore, for routine clinical use the dosimeter must be placed on the skin of the
patient or in accessible cavities when determining absorbed doses to a tumour or to
critical organs. For example, TL detectors have been inserted in the peritoneal cavity for
the measurement of the tumour dose arising from beta particles emitted by 131I [56].
During 1996, six patients [57] underwent eight RIT trials with 131I-labelled
monoclonal antibody in Helsinki University Central Hospital. The aim of the dose
estimations was to establish the magnitude of the absorbed doses to radiosensitive
organs. As described in detail in paper II, an independent method was developed in
order to determine the absorbed doses to the critical organs during SRT. The method is
based on the TL dosimeters placed on the skin of the patient. Therefore, four reference
points were marked on the skin of the patients for dose estimations. The first two
(posterior) points represented the right and left kidneys, and two points were selected on
the upper abdomen. Measurements with TL dosimeters were made by taping the
dosimeters to each reference point for a short period of time. Also, a phantom study was
performed to establish the method (paper II); the absorbed doses were measured with TL
detectors on the surface of the elliptical water phantom. The absorbed doses to the
points of interest, situated at various distances from the surface of the phantom, were
derived using the developed method. For comparison, the absorbed doses were also
measured with TL detectors situated inside the phantom at each point of interest.
3.3 Mixed neutron-gamma field
Boron neutron capture therapy (BNCT) [58,59,60] utilises epithermal neutrons for the
treatment of malignant tumours. In BNCT 10B is introduced into the tumour cells, and
the selective therapeutic dose is delivered by the neutron capture reaction 10B(n,α)7Li
when exposed to a neutron fluence. In order to evaluate the quality of an epithermal
beam for BNCT the desired epithermal neutron fluence and the undesired fast and
thermal neutron fluences as well as gamma fluence have to be determined. The gamma
dose to tissue when irradiated with an epithermal beam is composed by gamma-rays
present in the beam and from the capture reaction 1H(n,γ)2H.
The main dosimeters for characterising and controlling BNCT beams are
activation foils and paired ionisation chambers [30]. TL dosimeters are also used
because of the following advantages: i) with TL dosimeters it is possible to measure
depth dose curves and profiles at the same time, with one irradiation, and ii) because of
their small size TL dosimeters may be possible detectors for in vivo use. In previous
studies, TLD-700 (7LiF:Mg,Ti) TL dosimeters have been used in the gamma dosimetry
of BNCT [30,61,62,63]. However, difficulties have been encountered arising from a
small 6Li content in the enriched 7Li. Therefore, Raaijmakers et al.[30,31] have applied
a method in which the TL detectors are shielded from thermal neutrons using a 6Li
containing cap in the epithermal neutron beam of BNCT. Also, a theoretical method for
determining correction factors for thermal neutron sensitivity of TL detectors has been
developed [64].
As described in detail in paper III, two new TL dosimeter types3, MTS-Ns and
MCP-7s, were selected for use for neutron and gamma detection, respectively, in the
mixed neutron-gamma field of BNCT. For comparison the conventional TLD-100 and
TLD-700 detectors of Harshaw were also used. The measurements with TL dosimeters
were performed in the cylindrical PMMA (polymethylmetacrylate, (C5H8O2)n) and water
phantoms at the epithermal neutron beam of the TRIGA Mark II research reactor FiR 1
[65,66]. Reactor powers of 300 W for a PMMA phantom and 450 W for a water
phantom were used. The measurement time was half an hour for both phantom types.
TL detectors used for measurements in the water phantom were inserted in holes in
polypropylene discs. These holes were water isolated with paper and self-adhesive tape
of polypropylene on both sides of the discs. Since no thermal neutron shields were used
in the measurements, the correction for the thermal neutron sensitivity of the gamma
detectors were based on the theoretical method [64].
4 UNCERTAINTIES PRESENT IN THE MEASUREMENTS
The uncertainties of the absorbed dose measurements, performed with different
radiation qualities with TL dosimeters, are presented in Table 1. The chosen
measurement techniques as well as other major phenomena affecting on the total
uncertainty, and therefore the use of TL dosimeters in clinical applications in general,
are discussed in detail in this chapter.
4.1 TL characteristics
Thermoluminescent sensitivity may be defined [10] as the amount of light released by
the phosphor per unit of radiation exposure, i.e. as the TL signal per kerma or mean
absorbed dose. In the uncertainty evaluations of the papers I, II, III and IV, the
uncertainty arising from the detector sensitivity is taken into account concerning the
calibration of the detectors, since in practice the uncertainties caused by the calibration
source and detector sensitivity are linked together. Because of the deviation in readout
values of the individual detectors, illustrating the deviation of detector sensitivities
                                                          
3 TLD Niewiadomski & Co., Krakow, Poland.
specification of the uncertainty ui     estimated ui (1 S.D.) %
TLD-100 TLD-700 MCP-7s MTS-Ns CaSO4:Dy
X-ray γ n + γ n + γ n + γ n + γ γ
u1 = u(TL characteristics) 4 3 15 17 20 16 8
u2 = u(phantom measurements) 3 15 3 3 3 3




2)1/2 5 15 16 17 20 16 46
Table 1. The uncertainties present in the absorbed dose determinations of the clinical
applications of this thesis. The measurements with TL detectors were performed either in the
phantoms or in vivo using different radiation fields composed of X-rays, gamma rays (γ), or
neutrons and gamma rays (n + γ).
among a detector batch, individual calibration of the dosimeters was performed for all
the used solid discs and pellets (papers I, II, III, IV).
In the radiation field composed of X-rays, the absorbed dose measurements were
performed using TLD-100 detectors, which are sensitive enough (hundreds of counts per
mGy) for the purpose. The uncertainty of the whole calibration chain was estimated to
be 3% (1 S.D.) (Table 1 in paper I) including the uncertainty of the reference irradiation
(∼ 2% (1 S.D.)). Since the individual calibration, i.e. reference irradiation, was
performed using a 90Y/90Sr source, the reference air kerma, used for the determination of
the detector sensitivity, was calibrated for each X-ray quality of interest by using a
diagnostic dosimeter. Therefore, energy dependence (i.e. detector sensitivity as a
function of photon energy) of TLD-100 detectors [67,68] was not considered when
evaluating the uncertainties of the measurements (paper I). Also, in order to avoid the
uncertainty caused by the sensitivity change of the reader used over the irradiation
cycles, the calibration detectors irradiated with the 90Yr/90Sr source were read
frequently. The energy response of LiF TL detectors in a phantom differs from that in
free air [69], due to spectral differences caused by attenuation and scatter of X-rays. A
specific factor was used to correct for the isotropic angular distribution of photons
scattered from the phantom. Also, a conversion factor was used to convert between the
air kerma and tissue kerma. Both of these factors are slightly dependent on the X-ray
quality [70,71], and their uncertainty was estimated to be 2.5% (1 S.D.).
When measuring the absorbed doses from gamma radiation of
radioimmunotherapy, two types of TL detectors were used. CaSO4:Dy powder was
selected for use for patient studies because of its high sensitivity. However, the response
of CaSO4:Dy powder is highly energy dependent [67], and the relative sensitivity of the
CaSO4:Dy dosimeters varies as a function of distance from the irradiation source, since
the radiation arriving at the water-air interface has a large amount of low energy
scattered photons as a result of Compton interactions of the 364 keV gamma radiation.
Therefore, TLD-100 discs were used for determining the sensitivity of CaSO4:Dy
dosimeters as a function of distance from the source, as well as in the phantom
measurements performed to establish the developed method. In the Monte Carlo
simulation (paper II), the sensitivity of the used TLD-100 detectors was found to be
independent within 1% on the source to detector distance, and furthermore, energy in
the range of interest. The uncertainty caused by the energy dependence of CaSO4:Dy
detectors was estimated to be as high as 7% (1 S.D.) (Table 4 in paper II) even if
calibrated with TLD-100 detectors at various distances from the 131I source.
In BNCT, the absorbed dose to tissue is composed of dose components caused by
thermal, epithermal and fast neutrons, and gamma rays. These reaction specific dose
components must be known separately because of their different biological
effectiveness. In our study (paper III), 7LiF:Mg,Cu,P (MCP-7s) pellets with low
sensitivity for neutron radiation [72,73,74,75] were chosen for gamma separation.
However, they were found to be more sensitive to thermal neutrons than the literature
indicated [75], and therefore a detailed study was performed of the thermal neutron
sensitivities for both the MCP-7s and TLD-700 TL detectors (paper IV). According to
this study, the uncertainty in deriving the introduced figures of merit, used for
determining correction factors [64] for thermal neutron sensitivities, is approx. 13% for
both the MCP-7s and TLD-700 TL detectors. Therefore, the uncertainty caused by the
thermal neutron sensitivity is the dominant one compared with the other uncertainties
caused by the characteristics of the used TL materials (i.e. photon sensitivity or low
energy dependence [67,76]).
Experimentally observed thermal neutron sensitivities of the LiF TLD-100
detectors have been found to vary [77]. These variations in sensitivity are mainly due to
the self-shielding of TL detectors which can vary from a few percent to 50% depending
on the geometry, i.e. thickness, of the TL detector [14]. Therefore, besides the
traditional TLD-100 detectors also two-layer detectors (MTS-Ns) with an ultra-thin
active LiF:Mg,Ti layer on a passive base were selected for use as a neutron radiation
sensitive dosimeters for BNCT (paper III). These new detectors have been developed
and studied for personal neutron dosimetry [78], and found to provide essential
improvements in their characteristics especially with respect to self-shielding.
The response of TL material to neutrons is mainly dependent on the neutron
capture cross sections of its constituent elements [79]. The 6Li abundance in natural Li,
causing the thermal neutron sensitivity of LiF detectors, is about 7% [80]. Because of
the high capture cross section and, therefore, the high sensitivity of LiF detectors to
thermal neutrons, a lowered reaction power or shortened exposure time has to be used
for irradiation with a high neutron fluence rate of BNCT beams. However, those may
cause additional measurement uncertainty. Therefore, it might be useful to reduce the
neutron sensitivity of LiF detectors by adding 7Li to natural Li. According to statistical
analysis (paper VI), this reduction would not significantly increase the random
uncertainties of neutron fluence measurements. Problems may arise, however, from the
increased relative gamma sensitivity of these special LiF detectors with the reduced
neutron sensitivity. The gamma component of the induced TL signal would not be
insignificant compared to the neutron component, as it is when using TL detectors
composed of natural Li [81], and it might be difficult to separate the gamma and neutron
radiation induced signals. When using the commercial LiF:Mg,Ti detectors MTS-Ns
and TLD-100, the gamma subtraction had no significant effect on neutron dose: the
gamma ray induced TL signal had a magnitude of approx. 1% of the net TL signal
(paper III).
The reproducibility of the used solid detectors, TLD-100 and TLD-700 from
Harshaw and MTS-Ns and MCP-7s from TLD Niewiadomski & Co., were also studied
for the applied readout and annealing procedures (paper III). The reproducibility of the
MTS-Ns detectors was found to be 6% (1 S.D.) in the mixed neutron-gamma field. Even
though the standard annealing procedure [82] of LiF:Mg,Ti detectors (400°C ± 5°C for
one hour followed by 75°C ± 3°C for 24 h pre-irradiation and / or  110°C ± 3°C for 10
min post-irradiation) had been used, the reproducibility might not have improved since
the 400oC temperature annealing used regenerates these detectors completely, and
residual background readout values do not explain any instability in the detector
sensitivities. For this study, shortened annealing times were selected for use with the
aim of avoiding possible damages to TL detectors resulting from a long-term treatment
at a high temperature [24,25]. According to Carlsson [83] and Toivonen [25], the
shortened annealing procedure with a lower annealing temperature (approx. 300°C)
reproduces relative detector sensitivities better than the procedure where the TL
detectors are heated up to 400°C in free air.
The Harshaw detectors reproduced their readings accurately both after successive
gamma irradiations (1 S.D.=3% for TLD-100 and 1% for TLD-700) and irradiations in
the mixed neutron-gamma field in which the standard deviations (1 S.D.) were 4% and
2% for TLD-100 and TLD-700, respectively. Therefore, the lower reproducibility in
integrating the glow area of the neutron specific 270oC glow peak compared to the
210oC glow peak may be the source of uncertainty in the mixed field dosimetry with the
LiF:Mg,Ti detectors compared to gamma dosimetry. In our recent study (paper VI) on
the response characteristics of the LiF:Mg,Ti (MTS-Ns) detectors, the reproducibility of
the readout values has been improved by using an advanced readout technique with
linear heating and glow curve analysis. The reproducibility of the MTS-Ns detectors as
well as TLD-100 detectors may also be worsened by radiation damages due to neutron
radiation. Gambarini and Sinha Roy [81] have reported about irreversible radiation
damage in dosimeters having high sensitivity to thermal neutrons (TLD-600 with 96.5%
6Li), showing a memory effect on the previous thermal neutron irradiation history which
is not restored by anneal treatment. In the same study, 7LiF dosimeters showed a
response unaffected by the thermal neutron irradiation [81].
The MCP-7s detectors reproduced their readings accurately (1 S.D.=3%) after
successive gamma irradiations. After a few irradiations in the mixed neutron-gamma
field, the reproducibility of the TL readings was found to be only 7% (1 S.D.). The
reason for the poorer reproducibility was assumed to be in the high temperature glow
peaks of the 7LiF:Mg,Cu,P TL material generated by neutron radiation. These glow
peaks are not released during the annealing procedure used: it is recommended by the
manufacturer that MCP-7s detectors be prepared by heating at 240°C ± 5°C for ten
minutes, but since a sufficiently stable oven was unavailable to meet this temperature
requirement, the preparation was made by heating the detectors in a Vinten Toledo 654 -
reader4 with a reading temperature of 240°C for 40 s followed by rapid cooling with the
normal rate of the heater planchet (from 240°C to 80°C in about 20 seconds). By using
the recommended or longer annealing time with an advanced readout technique and
background subtraction method, the standard deviation, i.e. the random uncertainty, may
be smaller than the obtained 7% which represents gross signals without any background
subtraction. Furthermore, the use of an annealing temperature higher (e.g. 260°C) than
the standard 240°C improves the reproducibility of 7LiF:Mg,Cu,P detectors [84,85].
The accuracy of the measurements performed with TL detectors depends also on
the dose level used: for the most TL detectors, the induced TL signal as a function of
exposure is non-linear above a certain dose range. For example, the TL response is
supralinear for LiF:Mg,Ti detectors at the doses exceeding approx. 1 Gy, and therefore,
non-linearity corrections have to be introduced, especially if high-temperature peaks are
included in the glow curve [86,87]. In this study, because of the dose levels used
(varying from a few mGy (papers I, II, III) to hundreds of mGy (paper IV)), no
uncertainty was assumed to be caused by the supra- or sublinearity of the detectors
[88,89,90].
One of the important dosimetric characteristics of a TL material is fading, i.e. the
loss of signal during storage. The phenomenon has been studied extensively, both
experimentally and theoretically, for LiF:Mg,Ti detectors but the data reported in the
literature show considerable variation [91]. According to the manufacturers of the TL
detector types used (Harshaw, TLD Niewiadomski & Co.), fading varies from 5%/yr
(LiF:Mg,Ti and LiF:Mg,Cu,P) to 2% in one month (CaSO4:Dy) at room temperature.
Therefore, fading, as well as the uncertainty caused by it, were assumed to be negligible
for the measurements in which the solid detectors were read according to a fixed time
schedule (paper I), or immediately after use, preheated at 135°C for 16 s (papers II,III).
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Also, the readout procedure and the reader itself may cause uncertainty to the detector
readout values, i.e. to the sensitivity and reproducibility of the detectors. The readers
used, Vinten Toledo 654 (papers II, III, IV) and Dosacus5 (paper I), and the errors
caused by them, have been thoroughly studied by Toivonen [24,25], and the manual
planchet reader (Toledo 654) has been found more stable than an automatic reader based
on gas heating (Dosacus). It has also been stated [24,25] that it is possible to improve
the precision of TL measurements by improving readout techniques and readers; as
mentioned previously, the reproducibility of MTS-Ns detectors was improved by using a
Risø6 TL/OSL system with a linear heating profile and a glow curve analysis (paper VI).
In the measurements with TL detectors, additional uncertainty may also be caused
by detector handling. In this study, detectors were carefully handled either by
mechanical or vacuum tweezers with the aim of avoiding uncertainty. As TL detectors
lose sensitivity when frequently handled with mechanical tweezers [13], the detecting
surface of the dosimeters was not touched while using  mechanical tweezers. No
cleaning of the used detectors was needed nor, therefore, performed. Besides, cleaning is
good to be avoided [13] since it may change the crystalline surface structure of the
detector and, therefore, its response characteristics.
4.2 Phantom measurements
Additional uncertainty arises, when deriving absorbed doses to individual organs of the
Alderson-Rando phantom from the doses of the reference points, i.e. those points
measured directly with TL detectors or interpolated from them (paper I). The maximum
error, caused by the use of one point instead of the whole organ in determining the
absorbed dose of the organ, was found to be 11% (paper II). The organ used for this
approximation was the kidney, the volume of which was estimated from the literature
[92] to be 150 cm3. In the X-ray study, one or a few reference points represented the
smallest organs, but dozens of reference points were needed for large organs (paper I).
Therefore, an uncertainty caused by the use of points, representing the entire volume of
the organ, is estimated to be 3% (1 S.D.). Also, an uncertainty of approx. 5% is caused
to soft tissue in close contact with bone through interface effects.
In order to determine the uncertainties present in the phantom measurements,
performed with large number of consecutive TL detectors, Monte Carlo simulations
were used (paper V). In the simulations, detectors positions were selected to be the same
as those in actual measurements (paper III) at the BNCT beam of FiR 1. Also, the
perturbation of the neutron and gamma fluences caused by the polycarbonate
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((C16H14O3)n) frames, with the aid of which the TL detectors have been situated in the
measurements in the phantom, were determined using Monte Carlo simulations. As a
result, no significant fluence differences were found to occur in the cases of thermal and
epithermal neutrons or gamma rays: the neutron and gamma fluence rates were similar
within 3% for the simulations with and without neighbouring natLiF or 7LiF TL detectors
and polycarbonate frames at various measurement points in the phantom. The spatial
uncertainty of the measurements performed in the water phantom was ± 0.5 cm due to
uncertain positioning of the TL detectors in their thin holder frames (paper III).
According to the Burlin cavity theory [93], a one sided cavity effect occurs when
irradiating the phantom medium surrounded MCP-7s TL detectors (paper III). Because
of the one sided effect and the isotropic angular distribution of the gamma rays and
secondary electrons, the increase in the dose to the active LiF was estimated to be less
than 10%. Therefore, a reduction of 5% was made for the kerma, measured with MCP-
7s detectors, to correct for the error caused by the cavity effect.
Often, a considerable disturbance of the dose distribution near the interface
between the detector and medium may result due to the different scattering properties of
the two materials. Therefore, a study (paper II) was performed to determine whether the
phantom-TL material interface effects on the surface of the phantom, caused by the
nonequilibrium of secondary electrons, have to be taken into consideration in
determining absorbed doses from the readout values of the powdered CaSO4:Dy TL
detectors. The phantom study showed no thickness effect in the response of CaSO4:Dy
powder on the surface of the phantom. Therefore, no additional uncertainty was due to
measurements performed on the surface of the phantom where the requirement for the
secondary electron equilibrium is not completely met.
4.3 in vivo measurements
The uncertainty, present in the absorbed dose measurements performed in vivo (paper
II), was evaluated with the help of phantom measurements and calculations based on the
use of a point dose kernel technique. A bolus factor was determined with an accuracy of
4% from the phantom study to correct for the lack of back-scattering from the bolus
tissue in the reference point compared to that in the organ of interest. Also, the
attenuation coefficient for the broad beam geometry (including scattering) was
determined, and found to be 0.05 ± 0.01 cm-1 (paper II).
CT images of the patients were used in estimating the distances; the uncertainty in
measuring the individual distances from the (point) irradiation source to the reference
point or to the organ of interest was estimated to be 20% (1 S.D.). The uncertainty
caused by the use of a point source instead of a volume distribution of the activity
incorporated in the cancer tissue was calculated to be 10% (1 S.D.). As already
mentioned in chapter 4.2., the maximum error caused by the use of a point of interest
instead of the whole organ in determining the absorbed dose was found to be 11%. The
total uncertainty of measuring absorbed doses of the organs with the TL dosimeters
placed on the skin of the patient was found (paper II) to be below 50% (1 S.D.). The
total uncertainty is high compared to that of the phantom study (15%), and is mainly
explained by the uncertainty in the absorbed dose in the reference point, which arises
from the uncertain radioactivity distribution in the body (25%, 1 S.D.), and by the
characteristics of the disease: no exact tumour area can be delineated, and therefore the
measuring distances from the (point) irradiation source to the reference point or to the
organ of interest is uncertain.
5 DISCUSSION
In this thesis, the abilities of TL dosimeters for clinical dosimetry were studied in terms
of the precision and accuracy. The measurements with TL detectors, both in the
phantom and in vivo, were performed for clinical applications in which the dose
prediction is difficult and not as part of a routine verification procedure, such as RIT and
BNCT. Also, a phantom study with external X-rays was performed.
According to the ICRU [26], the accuracy in the dose determination should be
within ± 5%, or even lower, in the conventional radiotherapy. In diagnostics, there is not
so far these kinds of requirements for accuracy. Furthermore, since the radiation
damages in diagnostics are non-deterministic, the needed accuracy is not so high as in
therapy. Therefore, it is found (Table 1) that the uncertainty, caused by TL
characteristics and the measurement arrangements, is at a tolerable level in the case of
TLD-100 detectors exposed with diagnostic X-rays. As well as being the only
reasonable measurement technique, the TL detectors are also accurate enough for the
verification of the diagnostic studies in the anatomical phantoms.
CaSO4:Dy is a sufficiently sensitive TL material for the in vivo dosimetry of the
internal radionuclide source. However, CaSO4:Dy detectors are not tissue-equivalent
and their uncertainty, caused by the TL characteristics of the CaSO4:Dy dosimeters, is
high (Table 1). This inaccuracy is dominated by the energy dependence of the CaSO4:Dy
powder. Therefore, it was found to be essential that the most appropriate detector types,
i.e. independent of the energy, are selected for use in clinical applications in which the
irradiation of a wide energy range is applied.
When using an internal irradiation source, both in the phantom and in vivo, the
measurement uncertainties were dominant (Table 1) compared with that caused by the
TL characteristics. Therefore, special care has to be taken while positioning the TL
detectors for the (in vivo) measurements. Also, the patient anatomy and geometry as
well as the radionuclide distribution have to be studied thoroughly. If possible, the
placement of the detectors should be marked into the patient while studying his / her
anatomy e.g. with CT.
The low precision of the gamma dosimeter MCP-7s, irradiated in the mixed
neutron-gamma field of BNCT, is mainly due to the poor reproducibility of the detector.
Also, the inaccuracy of the gamma dose measurements, performed both with TLD-700
and MCP-7s detectors, is caused by the high uncertainty present in deriving the
correction factors for the thermal neutron sensitivity of the TL detectors used. The
reproducibility of MCP-7s detectors might be reduced considerably (e.g. to be < 1% as
in [89,94,95]) from the obtained 7% (paper III) by using a proper oven for annealing,
and the recommended annealing procedure. However, there are still questions about the
optimum thermal treatment and readout procedures for LiF:Mg,Cu,P TL detectors (e.g.
[84,96,97,98,99,100]). The use of thin layer detectors, such as MCP-7s, for the gamma
dosimetry should also be re-considered because of their uncertainty due to the cavity
effect.
The uncertainty of the thermal neutron correction factor mainly arises (paper IV)
from the uncertainty of the spectrum averaged fluence-to-kerma conversion factor, used
in theoretical derivation of the correction factor [64]. The uncertainty of the used
fluence-to-kerma conversion factor is 10% [101], and it also causes uncertainty to
(relative) neutron fluence measurements (paper III) performed with TLD-100 and MTS-
Ns detectors. As well as in the case of the external X-ray irradiation beam, the
measurement arrangements in the phantom did not increase significantly the total
uncertainty (Table 1) when irradiating at the mixed neutron-gamma field of BNCT. It
was found that even if lower precision, the accuracy of the dose estimations, performed
with TL detectors in the phantoms, is not essentially worse when compared with that
performed with ionisation chambers [102].
The use of TL detectors for clinical dosimetry may be laborious. In many
applications a large number of TL detectors have to be used for the measurement of the
absorbed dose which requires care and accuracy in order to keep the detectors in order.
Also, the detectors should be handled with care in order to avoid additional uncertainty
and loss of sensitivity (see e.g. ref. [13]). The recommended readout and annealing
procedures should also be followed even though they are cumbersome in many cases. In
spite of these drawbacks, TL detectors may be for many clinical applications the only
available, and reasonable, measurement technique. If handled with care, their
uncertainties can easily be reduced, if not to a tolerable level, but to the same level
achieved with other methods.
6 SUMMARY
In many clinical applications, the use of TL dosimeters is the only available tool for
dosimetry. TL detectors are especially useful in difficult geometries where the best use
can be made of their advantages such as their stand alone character and small physical
size. In this thesis, the abilities of TL detectors were studied in different clinical
applications, in which TL dosimeters were found to be capable of making absorbed dose
measurements.
Paper I contains organ dose determinations of X-ray examinations using TL
detectors. The measured absorbed doses are compared with the computed doses. TL
detectors are found to be accurate within 5% (1 S.D.), and are therefore capable of
verifying the calculated absorbed doses.
In Paper II, a method for determining the absorbed doses to organs in systemic
radiation therapy is introduced. The developed method is based on TL detectors placed
on the patient’s skin. A phantom study is carried out to establish the method. It was
found that in SRT the TL method can be used to estimate the absorbed doses to those
critical organs near the body surface within 50%.
The characteristics of TL detectors, irradiated at the mixed neutron-gamma field of
BNCT, is studied in Paper III. A code of practice for relative neutron fluence
measurements, performed with TL detectors in the mixed neutron-gamma field of
BNCT, is presented. TL detectors (both the thin-layer MTS-Ns and TLD-100) were
found to be able to measure the neutron dose component with an accuracy of 16%. Also,
a new gamma dosimeter, the MCP-7s, was found to be less sensitive to thermal neutrons
and therefore more suitable for BNCT dosimetry than the conventional TLD-700. An
experimental method for determining correction factors for thermal neutron sensitivity
of TL detectors used in gamma dosimetry of BNCT is presented in Paper IV.
A Monte Carlo study was performed on the influence of adjacent TL detectors to
TL readings in simultaneous measurements at BNCT beams (Paper V). In the study, it
is concluded that several TL dosimeters can be used in simultaneous measurements in
the phantoms without the need for the correction factors arising from the shielding of
the other TL dosimeters present in the measurement, or the polycarbonate frame used in
the measurements.
Paper VI is a statistical analysis of the effects of sensitivity reduction on the
random uncertainty of the measured gamma and neutron doses at the BNCT beam. It
was found that the reduction does not significantly increase the random uncertainties.
The uncertainties of TL dosimeters were found to be high but not essentially more
significant than those in other measurement techniques used for clinical dosimetry.
Also, the precision and accuracy of the absorbed dose measurements performed with TL
detectors may be improved by: i) selecting the appropriate detector type (e.g. energy
dependence) for the measurement purpose, ii) using the recommended thermal treatment
procedure, and iii) careful handling of the detectors. It is shown in this thesis that the
absorbed gamma doses can be measured with TL detectors within 20% in a mixed
neutron-gamma field, which enables in vivo measurements at BNCT beams with
approximately the same accuracy. However, as reported in paper II, a major uncertainty
in the in vivo measurements may arise from the placement of the TL detectors.
Therefore, the positioning of the detectors, as well as the other arrangements of the
measurement, have to be planned carefully beforehand, and if possible, also verified
while studying the anatomy of the patient.
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